Metastatic melanoma: Spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 1, 2013, Pages 92-96

  Maire, C ^a   Vercambre Darras, S ^a   Devos, P ^a   D'Herbomez, M ^a   Dubucquoi, S ^a   Mortier, L ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; THYROID ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOTHERAPY; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; ANALYSIS OF VARIANCE; AUTOANTIBODIES; AUTOIMMUNITY; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84872875599     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04364.x     Document Type: Article

References (26)

1. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46: 270-283.
2. Lee CC, Faries MB, Wanek LA, et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 2008; 26: 535-541.
3. Lee CC, Faries MB, Wanek LA, et al. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 2009; 27: 3489-3495.
4. Vercambre-Darras S, Dubucquoi S, Fajardy I, et al. Does spontaneous autoimmunity improve survival in visceral metastatic melanoma? Br J Dermatol 2007; 157: 413-415.
5. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-718.
6. Fairweather D, Frisancho-Kiss S, Rose NR,. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008; 173: 600-609.
7. Lee CC, Faries MB, Wanek LA, et al. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 2009; 27: 3489-3495.
8. Baumgartner JM, Gonzalez R, Lewis KD, et al. Increased survival from stage IV melanoma associated with fewer regulatory T cells. J Surg Res 2009; 154: 13-20.
9. Dherbomez M, Sapin R, Gasser F, et al. Concordance of eight kits for antithyroid peroxidase autoantibodies determination. Clin Chem Lab Med 2000; 38: 561-566.
10. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997; 40: 1601-1611.
11. Hernberg M, Turunen JP, Muhonen T, et al. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy. J Immunother 1997; 20: 488-495.
12. Mitchell MS, Harel W, Kempf RA, et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990; 8: 856-869.
13. Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-482.
14. van den Boorn JG, Picavet DI, van Swieten PF, et al. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol 2011; 131: 1240-1251.
15. Becker JC, Varki N, Gillies SD, et al. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 1996; 93: 7826-7831.
16. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
17. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23: 6043-6053.
18. Satzger I, Meier A, Schenck F, et al. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer 2007; 121: 2562-2566.
19. Bouwhuis MG, Suciu S, Collette S, et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 2009; 101: 869-877.
20. Nordlund JJ, Kirkwood JM, Forget BM, et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983; 9: 689-696.
21. Duhra P, Ilchyshyn A,. Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin Exp Dermatol 1991; 16: 303-305.
22. Das PK, van den Wijngaard RM, Wankowicz-Kalinska A, et al. A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo. Trends Immunol 2001; 22: 130-136.
23. Chan C, O'Day J,. Melanoma-associated retinopathy: does autoimmunity prolong survival? Clin Experiment Ophthalmol 2001; 29: 235-238.
24. Schioth HB, Prusis P, Muceniece R, et al. Thyrotropin releasing hormone (TRH) selectively binds and activates the melanocortin 1 receptor. Peptides 1999; 20: 395-400.
25. Slominski A, Wortsman J, Kohn L, et al. Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. J Invest Dermatol 2002; 119: 1449-1455.
26. Deshmukh US, Bagavant H, Lewis J, et al. Epitope spreading within lupus-associated ribonucleoprotein antigens. Clin Immunol 2005; 117: 112-120.